Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), November 2008
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001872
  Purpose

Blood contains different kinds of cells, white blood cells, red blood cells, and platelets. In order to treat certain diseases, specific cell types can be removed from blood and transplanted into patients. The process of removing white blood cells for the treatment of leukemia is called apheresis.

This study will make available blood cell collections from volunteers genetically matched to various degrees with recipients in order to test and, if necessary, refine the process of removing white blood cell T-lymphocytes.


Condition
Graft vs Host Disease
Hematologic Neoplasm

MedlinePlus related topics: Bone Marrow Transplantation Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Apheresis of Family Members of Patients Undergoing Allogeneic Bone Marrow Transplantation. A Pre-Clinical Study of Selective Depletion of Donor Lymphocytes to Prevent Acute Graft-Versus-Host Disease

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 40
Study Start Date: February 1999
Detailed Description:

This protocol has been written to make available apheresis collections from volunteers matched to various degrees with recipients in order to test and, if necessary refine, the selective immunodepletion procedure prior to introducing it in a clinical trial.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Family members of patients admitted to NHLBI allogeneic BMT protocols.

Ages 18 and older and less than age 65.

Parent of patient (obligate haplotype match) OR HLA 3/6, 4/6/, 5/6/, or 6/6 match with patient.

Research apheresis available from patient.

EXCLUSION CRITERIA:

Pregnancy or lactation.

HLA type unknown.

More than one haplotype mismatch with patient.

History of any immunosuppressive disease

History of chronic viral antigenic stimulus

Venous access inadequate.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001872

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 990037, 99-H-0037
Study First Received: November 3, 1999
Last Updated: November 25, 2008
ClinicalTrials.gov Identifier: NCT00001872  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Volunteer
Leukocyte Donors
Family Members
Leukocyte Collection
No Reimbursement

Study placed in the following topic categories:
Hematologic Neoplasms
Graft versus host disease
Hematologic Diseases
Graft vs Host Disease
Homologous wasting disease

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Immune System Diseases

ClinicalTrials.gov processed this record on January 15, 2009